Prescribed by an oncologist for the treatment of women with: 🔹 Breast Cancer: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. 🔹 Treatment Regimen: Used in combination with an aromatase inhibitor (e.g., letrozole) or with fulvestrant (in women who have received prior endocrine therapy).

Dosage and administration

Sales Unit: Carton containing 21 capsules. Strength: 125 mg per capsule. ⚠️ APPLICATION INSTRUCTIONS: 28-Day Cycle Schedule: The recommended dose is 1 capsule (125 mg) taken once daily for 21 consecutive days, followed by a mandatory 7-day treatment-free period. Administration: Capsules must be taken with food (to ensure proper absorption). Swallow whole; do not open, chew, or crush the capsules. ✋ Dietary Warning: Strictly avoid consuming grapefruit, pomelo, and their juices during treatment, as they can severely alter the medication's metabolism.

⛔ Drug Interactions: Concomitant use with strong CYP3A inhibitors or inducers (e.g., clarithromycin, ketoconazole, St. John’s wort, carbamazepine) is strictly contraindicated. Severe hepatic or renal impairment. Pregnancy and breastfeeding (highly teratogenic; women of childbearing potential must use reliable contraception). Children and adolescents under 18 years of age.

Treatment requires rigorous monitoring of complete blood counts, especially during the first two months. Potential side effects include: 🩸 Blood Counts: Neutropenia (very common, requires monitoring and possible dose interruption/reduction), leukopenia, anemia, thrombocytopenia. 🦠 Immunity: Increased susceptibility to infections (especially upper respiratory tract infections). 🤢 Gastrointestinal: Stomatitis (mouth sores), nausea, diarrhea, decreased appetite. 💤 General: Severe fatigue, asthenia. 💇♀️ Skin & Hair: Hair thinning/loss (alopecia), dry skin.

Reampla 125 — Palbociclib 125 mg, 21 pcs, Pfizer

100% original product

Active ingredient

Palbociclib

Manufacturer

Pfizer

Dosage 125 mg

Dosage form Capsules

Capsules per pack 21

Reampla 125 Capsules — Palbociclib 125 mg (21 Caps) Pfizer

Name: Reampla 125
Brand: Pfizer
SKU: PROD-237
Price: 28775 UAH
Availability: PreOrder

28775₴ ~~33202₴~~ -13% On order · from 7 days

Reampla 125 mg (Palbociclib) is an original, targeted anti-cancer medication. It acts as a highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking these enzymes, the medication stops the growth and division of malignant cells, effectively preventing the progression of hormone-driven breast cancer.

Manufacturer: Pfizer (USA). 🇹🇷 Note: This product holds official Turkish registration. It is a 100% original medication manufactured by the global pharmaceutical giant Pfizer, packaged for the Turkish domestic market under the local brand name Reampla. Globally, including in the US and Europe, this exact medication is widely known under the brand name Ibrance.

Key Features:

✅ Global Standard: One of the most thoroughly researched and effective first-line treatments for metastatic breast cancer.
✅ Synergistic Effect: When combined with hormone therapy, it provides prolonged tumor suppression.
✅ Convenient Cycle: A pack of 21 capsules provides exactly the right amount for the active continuous dosing phase of a 28-day cycle.

Prescribed by an oncologist for the treatment of women with:

🔹 Breast Cancer: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
🔹 Treatment Regimen: Used in combination with an aromatase inhibitor (e.g., letrozole) or with fulvestrant (in women who have received prior endocrine therapy).

Sales Unit: Carton containing 21 capsules. Strength: 125 mg per capsule.

⚠️ APPLICATION INSTRUCTIONS:

28-Day Cycle Schedule: The recommended dose is 1 capsule (125 mg) taken once daily for 21 consecutive days, followed by a mandatory 7-day treatment-free period.
Administration: Capsules must be taken with food (to ensure proper absorption). Swallow whole; do not open, chew, or crush the capsules.
✋ Dietary Warning: Strictly avoid consuming grapefruit, pomelo, and their juices during treatment, as they can severely alter the medication's metabolism.

⛔ Drug Interactions: Concomitant use with strong CYP3A inhibitors or inducers (e.g., clarithromycin, ketoconazole, St. John’s wort, carbamazepine) is strictly contraindicated.
Severe hepatic or renal impairment.
Pregnancy and breastfeeding (highly teratogenic; women of childbearing potential must use reliable contraception).
Children and adolescents under 18 years of age.

Treatment requires rigorous monitoring of complete blood counts, especially during the first two months. Potential side effects include:

🩸 Blood Counts: Neutropenia (very common, requires monitoring and possible dose interruption/reduction), leukopenia, anemia, thrombocytopenia.
🦠 Immunity: Increased susceptibility to infections (especially upper respiratory tract infections).
🤢 Gastrointestinal: Stomatitis (mouth sores), nausea, diarrhea, decreased appetite.
💤 General: Severe fatigue, asthenia.
💇‍♀️ Skin & Hair: Hair thinning/loss (alopecia), dry skin.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 09.04.2026